ADDF awards $210 glipizide.
ADDF awards $210,300 to Amicus Therapeutics to judge PCs for treating Alzheimer’s disease The Alzheimer’s Medication Discovery Basis announced today that it has awarded a grant of $210,300 to Amicus Therapeutics to evaluate small-molecule, orally shipped pharmacological chaperone substances as a novel strategy for treating Alzheimer’s disease glipizide . Amicus provides discovered an apparent link between numerous lysosomal enzymes and accumulation of the beta-amyloid and p-tau deposits seen in the brain of Alzheimer’s individuals. This process may be broadly relevant to diseases where an increase in the activity of a particular protein might provide therapeutic benefit. (more…)